|
gptkbp:instanceOf
|
gptkb:drug
amphetamine
stimulant
norepinephrine reuptake inhibitor
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06BA23
|
|
gptkbp:brand
|
gptkb:Focalin
|
|
gptkbp:CASNumber
|
564-02-3
|
|
gptkbp:chemicalClass
|
piperidine
|
|
gptkbp:contraindication
|
anxiety
glaucoma
Tourette syndrome
agitation
tics
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1990s
|
|
gptkbp:form
|
extended-release capsule
immediate-release tablet
|
|
gptkbp:has_stereochemistry
|
d-threo
|
|
gptkbp:hasEnantiomer
|
gptkb:methylphenidate
|
|
gptkbp:hasMolecularFormula
|
C14H19NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dexmethylphenidate
|
|
gptkbp:isomerOf
|
gptkb:levomethylphenidate
|
|
gptkbp:IUPACName
|
(R)-methyl 2-phenyl-2-(2-piperidyl)acetate
|
|
gptkbp:KEGGID
|
D07713
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:mechanismOfAction
|
blocks reuptake of norepinephrine and dopamine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
5362440
4514932
DB06701
|
|
gptkbp:relatedTo
|
gptkb:methylphenidate
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
abdominal pain
headache
nervousness
insomnia
dry mouth
decreased appetite
increased blood pressure
|
|
gptkbp:UNII
|
140VQM8K9T
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
|
|
gptkbp:bfsParent
|
gptkb:methylphenidate
|
|
gptkbp:bfsLayer
|
6
|